Les traitements adjuvants du cancer du sein précoce sans atteinte ganglionnaire

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Revue de Médecine Interne

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S0248-8663(05)82149-6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

  1992cited by this paper
• Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer.

  1992cited by this paper
• Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.

  1992cited by this paper
• Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.

  1992cited by this paper
• Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.

  1992cited by this paper
• c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse.

  1992cited by this paper
• Intravascular ultrasound imaging combined with coronary angioplasty.

  1992cited by this paper
• Micrometastases in breast cancer: long-term follow-up of the first patient cohort.

  1991cited by this paper
• Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers.

  1991cited by this paper
• How to use prognostic factors in axillary node-negative breast cancer patients.

  1990cited by this paper
• Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

  1990cited by this paper
• Cathepsin D and prognosis in breast cancer.

  1990cited by this paper
• Growth rate, kinetics of tumor cell proliferation and long‐term outcome in human breast cancer

  1989cited by this paper
• Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.

  1989cited by this paper
• Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer.

  1989cited by this paper
• Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

  1989cited by this paper
• Flow cytometry using paraffin-embedded tissue: five years on.

  1989cited by this paper
• Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.

  1989cited by this paper
• Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.

  1989cited by this paper
• Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.

  1989cited by this paper
• Cytometric characterization and clinical course of breast cancer diagnosed in a population‐based screening program

  1989cited by this paper
• The Multivariate Prognostic Index and nuclear DNA content are independent prognostic factors in primary breast cancer patients.

  1989cited by this paper
• Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer.

  1989cited by this paper
• Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.

  1989cited by this paper
• A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.

  1989cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Review: Steroid Receptors, Cellular Kinetics, and Lymph Node Status as Prognostic Factors in Breast Cancer

  1988cited by this paper
• Prognostic value of estrogen and progesterone receptors in operable breast cancer: Results of a univariate and multivariate analysis

  1988cited by this paper
• Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The influence of hormone receptors and hormonal adjuvant therapy on disease-free survival in breast cancer: a multifactorial analysis.

  1986cited by this paper
• Role of steroid hormone receptors as prognostic factors in primary breast cancer.

  1986cited by this paper
• Estrogen receptor: A prognostic factor in breast cancer

  1981cited by this paper
• Estrogen receptor protein in breast cancer as a predictor of recurrence

  1981cited by this paper
• Management and survival of female breast cancer: Results of a national survey by the American college of surgeons

  1980cited by this paper
• Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients

  1978cited by this paper
• Cancer of the breast: Size of neoplasm and prognosis

  1969cited by this paper

• Unexpected association between breast cancer and molar pregnancy in a 52-year-old woman: A case report

  2023cites this paper